The estimated Net Worth of David Patience is at least $103 Mille dollars as of 9 April 2024. David Patience owns over 37,468 units of Accelerate Diagnostics Inc stock worth over $102,581 and over the last 2 years David sold AXDX stock worth over $0.
Sign up
David Patience AXDX stock SEC Form 4 insiders trading
David has made over 11 trades of the Accelerate Diagnostics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently David exercised 37,468 units of AXDX stock worth $60,323 on 9 April 2024.
The largest trade David's ever made was exercising 37,468 units of Accelerate Diagnostics Inc stock on 9 April 2024 worth over $60,323. On average, David trades about 3,149 units every 23 days since 2023. As of 9 April 2024 David still owns at least 63,715 units of Accelerate Diagnostics Inc stock.
You can see the complete history of David Patience stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's David Patience's mailing address?
David's mailing address filed with the SEC is C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON, AZ, 85714.
Insiders trading at Accelerate Diagnostics Inc
Over the last 12 years, insiders at Accelerate Diagnostics Inc have traded over $26,833,308 worth of Accelerate Diagnostics Inc stock and bought 16,366,880 units worth $209,384,489 . The most active insiders traders include Jack W Schuler, Larry N Feinberg e Matthew Strobeck. On average, Accelerate Diagnostics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $132,645. The most recent stock trade was executed by Hany Massarany on 28 June 2024, trading 4,737 units of AXDX stock currently worth $7,627.
What does Accelerate Diagnostics Inc do?
accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
What does Accelerate Diagnostics Inc's logo look like?
Complete history of David Patience stock trades at Accelerate Diagnostics Inc
Accelerate Diagnostics Inc executives and stock owners
Accelerate Diagnostics Inc executives and other stock owners filed with the SEC include:
-
John Phillips,
Chief Executive Officer, Chief Operating Officer, Director -
Steve Reichling,
Chief Financial Officer -
Jack Phillips,
CEO, Pres & Director -
Ron Price,
Senior Vice President, Head of Commercial Operations, Americas -
Roland Diggelmann,
Independent Director -
Louise Francesconi,
Independent Director -
Steve Reichling,
CFO & Chief Accounting Officer -
Ron Price,
Chief Commercial Officer of Americas -
Charles Watts,
Independent Director -
Frank ten Brink,
Independent Director -
Matthew Strobeck,
Independent Director -
Jack Schuler,
Independent Director -
Mark Miller,
Independent Director -
Thomas Brown,
Independent Director -
John Patience,
Independent Chairman of the Board -
Nedal Safwat,
Chief Strategy Officer -
Dr. Lawrence Mertz,
Sr. VP and Head of R&D -
John Meduri,
Chief Strategy Officer -
Laura Costa,
Sr. VP & Head of Global Customer Support -
Cherif Bousselham,
Sr. VP & Head of Sales - EMEA -
Gretchen Strohminger,
Sr. VP and Head of HR & Culture -
Michael Bridge,
Sr. VP, Gen. Counsel & Sec. -
Laura Pierson,
Investor Relations Officer -
Larry N Feinberg,
10% owner -
Pete Bantock,
CHIEF COMMERCIAL OFFICER -
Lawrence Mehren,
PRESIDENT AND CEO -
Marran H. Ogilvie,
Director -
Jennifer Regan,
Director -
Mark S. Black,
Director -
Ventures, Llc Abeja,
10% owner -
Romney Humphries,
Chief Scientific Officer -
Larry Michael Mertz,
Chief Technology Officer -
Hany Massarany,
Director -
Jack Phillips,
Chief Executive Officer -
Wayne Burris,
Director -
David Patience,
Chief Financial Officer